Member Info for Laura2022

Sienna

There was an update published by both DoseMeRx and Pyc in june

Aber

Not sure but would imagine having got this far SAR may well use/be using PYC again at yhis pivotal stage

published 6th aigust 2024

this rn compound is what pyc (with their experience in dnadr) helped with

dna repair, and discuss its potential as a cancer therapeutic target. therapeutic targeting of rhno1 holds promise for tumors with elevated drs as well as tumors with dna repair deficiencies, including ****logous recombination dna repair deficient (hrd) tumors. further investigation into rhno1 function in cancer, and development of approaches to target rhno1, are expected to yield novel strategies for cancer treatment.

But that's not the ACTUAL real spreas as u well know

I can see from your previous 50 posts you don't have much of use to say on investments

Please don't lie

It's 0.818 to 0.87p = about 6%

Nice try

Https://www.nature.com/articles/s41388-024-03117-x

Https://www.msn.com/en-in/health/health-news/new-nanoparticle-immunotherapy-delays-prostate-cancer-resistance-study/ar-AA1olfkF?ocid=BingNewsSerp

Looks like it's moving

Fantastic KingHomer

PYC helped with this lead asset on Sar

This is from SAR today

Further references to SRA737

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00548-w

RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer

https://www.nature.com/articles/s41388-024-03117-x

Rob

All credit partic also to KingHomer, Trench123 and Debull

31st May 2023

The University successfully applied for funding under the UK Research and Innovation (UKRI) Higher Education Innovation Funding (HEIF) scheme, part of which will be used to retain Physiomics for a pilot project to analyse data generated by its innovative new testing platform in order to better understand how the platform might guide later stages of pharmaceutical research into cancer therapies, including pre-clinical and human studies.

The project is expected to be concluded over the next two months, and a longer-term collaboration is currently under discussion.

 

Physiomics CEO, Dr Jim Millen commented:

"We are delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities. We look forward to working with Dr Campbell and her colleagues and believe that both our analytical capabilities, as well as our contacts and experience within the pharmaceutical industry, could add real value to the initiative."

 

No problem

Hi violet

PYC.provide the dosing technology NOT the actual drugs

We use our expertise to analyse the drugs ( just as important)

Hope that helps

£5mln would still only be x 5 revenues

GE recently bought this A.I software tool company

Shows the value potential for PYCs business going forward

GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a provider of integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.

"We are pleased to bring innovative technology from Intelligent Ultrasound into GE HealthCare’s Ultrasound portfolio, allowing us to fully integrate these solutions into our systems to help clinicians improve workflow, reduce repetitive tasks, and simplify exams,” s

Nt to buy again at 85

Delayed trades ?

Yes GB

Seems like more large buys to show

Pumpkin

How sad going round every board (pxs rrr etc)

· Increased investment in business development and marketing, culminating in a peak pipeline value at over £1.5m (unweighted) as announced on 7 March 2024, a record year (FY2023/24) for total value of new contracts won, and over £500k of revenue already contracted for next year (FYE 2025), with additional revenue contracted into the following two years (FYE 2026 and 2027).